Signifor LAR Therapy Controls Acromegaly Better: Novartis

Swiss drug maker Novartis said its Phase III trial of Signifor LAR therapy was more effective in controlling acromegaly disease compared to other existing therapies.

Swiss drug maker Novartis (NVS) said its Phase III trial of Signifor LAR therapy was more effective in controlling acromegaly disease compared to other existing therapies.

“These results strengthen our understanding of this rare endocrine disorder and suggest pasireotide LAR may offer benefit for acromegaly patients whose disease is not fully controlled on their current therapy. As part of our long-standing commitment to transforming the care of rare pituitary diseases, we are working to bring this potentially meaningful solution to the acromegaly community,” said Alessandro Riva, president, Novartis Oncology ad interim and Global Head, Oncology Development and Medical Affairs.

Novartis files application with FDA for Zometa
Novartis Pharmaceuticals has submitted an application to the Food and Drug Administration, seeking marketing authorization for Zometa in the

Benign tumour in pituitary gland that secretes excess growth hormone leads to acromegaly that causes enlargement of body parts, including hands, feet and facial features.

The Phase III trial that was done on 198 patients examined pasireotide LAR 40 mg or pasireotide LAR 60 mg versus continued open-label treatment with octreotide LAR 30 mg or lanreotide Autogel 120 mg (the control group) for 24 weeks.

Source-Medindia

AIIMS Doctors Remove Tumor Responsible for Gigantic Growth in Woman
Doctors at the All India Institute of Medical Sciences (AIIMS) have been able to ‘cure’ a 7.8 feet woman after removing a tumor.

Potential Therapeutic Target for Cushing's Disease Identified
A protein that drives the formation of pituitary tumors in Cushing's disease has been discovered by scientists.

Medicine Helps Short Children 'Rise in Stature' With Growth Hormone Therapy
Growth hormone therapy can significantly increase height in children with short stature, says a new study.